A Fish That Grows Old In Months Shows Why Kidneys Age, and How to Stop It

Somewhere in a tank at a research laboratory in Maine, a killifish is showing its age. Its spine has begun to curve. Its movements are slower than they once were. And inside its body, something dramatic is happening at a microscopic scale—the blood vessels that nourish its ageing kidneys are quietly disappearing, one by one.

This tiny fish won’t see its second birthday. But what researchers have discovered about its failing kidneys could reshape how we think about one of the human body’s most common problems: the slow, relentless decline of kidney function as we grow old.

The African turquoise killifish isn’t chosen for research because it’s remarkable in any obvious way. It’s actually the opposite—it’s remarkable for being unremarkably brief. In a laboratory, these fish live about four to six months, with some reaching eighteen weeks. That’s compressed into a single season what takes us three-quarters of a century. Their kidneys age too, following patterns that closely mirror what happens in ageing human kidneys. And because they age so quickly, they offer scientists something invaluable: the chance to watch a lifetime of kidney deterioration unfold in weeks rather than years.

A team led by Anastasia Paulmann at the Mount Desert Island Biological Laboratory in Bar Harbor, Maine decided to use this speed to their advantage. They wanted to understand exactly what happens to kidney blood vessels as we age—and whether an existing drug might slow the process down. The results, published recently in Kidney International, reveal something unexpected: the damage isn’t inevitable, and a medication used for millions of diabetes patients might offer protection most researchers never expected it to provide.

The Vessels Vanish

Consider what an ageing kidney looks like under a microscope. A young kidney’s blood vessels form an intricate, densely branched network—thousands of tiny capillaries weaving through the tissue like the finest lace. These vessels do essential work. They filter waste from the blood, reabsorb water and nutrients, and maintain the precise chemical balance that keeps us alive. But as kidneys age, something strange happens. The vessels don’t just become narrower or weaker. They disappear.

Paulmann’s team visualised this process in stunning detail. Using a technique that fills blood vessels with fluorescent dye, then imaging entire organs in three dimensions, they could watch how the killifish kidney transforms with age. In young fish, the vascular networks are intricate and heavily branched. In old fish—which is to say, in fish that have lived just a few months—those networks look sparse and threadbare. The total vessel volume drops dramatically. Capillary density declines sharply. The dense branching pattern collapses. By the time these fish reach old age, they’ve lost more than half of their blood vessel structure.

This isn’t merely an anatomical curiosity. When blood vessels vanish, the tissue they were nourishing becomes starved of oxygen. That hypoxia triggers a cascade of problems: the surrounding cells begin to dysfunction, inflammation sets in, and fibrosis—the formation of scar tissue—accelerates. It becomes a self-reinforcing spiral of damage. Lose enough vessels, and the kidney simply stops working properly.

In humans, this same process happens. We know that microvascular rarefaction—the medical term for the progressive loss of capillaries—is a hallmark of kidney ageing. What we don’t fully understand is why it happens, or how to prevent it. The killifish, with its telescoped timeline, offered a chance to finally probe these mechanisms in depth.

The team found that ageing in these fish brings all the hallmarks of kidney decline. Glomeruli—the structures that actually do the filtering—become scarred and less efficient. Around six times as many of them show signs of sclerosis in old fish compared to young ones. Tubules atrophy. The tissue becomes increasingly fibrosed. Protein leaks into the urine, suggesting the filtering barrier has become compromised. It’s a comprehensive picture of age-related kidney disease, compressed into a matter of weeks.

The Metabolic Shift

But the researchers wanted to understand not just what breaks down, but why. So they sequenced the RNA from individual kidney cells, analysing which genes were switched on and off at different ages. What they discovered was a profound metabolic shift.

Young kidney cells rely primarily on oxidative phosphorylation—an efficient way of extracting energy from nutrients using mitochondria, the cell’s powerhouses. It’s the metabolic equivalent of running a steady flame under a kettle. But in old kidney cells, that efficient process breaks down. The cells shift toward glycolysis, a far less efficient pathway for generating energy. It’s like switching from that controlled flame to trying to heat water by striking matches. You get some energy, but you’re spending far more fuel to get it.

This wasn’t happening in just one cell type. It was widespread across all the major kidney cell populations—the cells that filter blood, the cells that reabsorb water and nutrients, the endothelial cells that line the vessels, even the support cells that stabilise the vascular network. Every major compartment of the kidney was becoming metabolically inflexible, losing its ability to respond to changing energy demands. And alongside this metabolic collapse came a surge in inflammatory signals—the tissue-damaging proteins that fuel “inflammaging,” the low-grade chronic inflammation that accompanies growing old.

The loss of intercellular communication was equally striking. The researchers used a computational approach called CellChat to map the intricate dialogue between different cell types in the kidney. In young kidneys, this conversation is rich and complex. Cells send each other signals via adhesion molecules, growth factors, and extracellular matrix components. It’s a constant back-and-forth of instructions and support. In old kidneys, that conversation largely shuts down. The total number of distinct cell-to-cell signalling interactions dropped dramatically. The cells were becoming isolated from one another, unable to coordinate the repairs and maintenance that keep tissue healthy.

A Molecule with Promise

All of this raised an obvious question: could any of it be reversed? The researchers chose to test a drug that seemed like an unlikely candidate for kidney rejuvenation. SGLT2 inhibitors are a class of medication used primarily to help diabetic patients control their blood sugar levels. The mechanism is straightforward—they block a transporter protein in the kidney that normally reabsorbs glucose filtered from the blood, allowing excess glucose to be excreted in the urine instead. Simple pharmacology, well understood, hardly revolutionary.

But in recent years, something puzzling has emerged from clinical trials. Patients taking SGLT2 inhibitors don’t just have better blood sugar control. They also have better kidney outcomes and better heart outcomes, often regardless of whether they actually have diabetes. Something about blocking this transporter seems to be protective, though the mechanism remains incompletely understood. The researchers hypothesised that perhaps this protection extended to the ageing process itself. Could SGLT2 inhibitors preserve the kidney’s vascular structure as it ages?

To test the idea, they added the drug dapagliflozin to the fish food—a practical solution that allowed them to treat fish continuously throughout their lives. They confirmed the drug was working using isolated kidney tubules from treated fish, which showed dramatically reduced glucose uptake when tested ex vivo. Then they waited and watched what happened to ageing kidneys receiving this subtle pharmaceutical nudge.

What they found was striking. The drug didn’t prevent ageing—the treated fish still grew old at the normal accelerated pace, their organs still showed signs of cellular stress. But the blood vessels told a different story. Kidneys from SGLT2-inhibited fish maintained far more of their vascular structure. The total vessel volume was significantly higher. The branching complexity was preserved. Most remarkably, the vasculature maintained a more youthful transcriptional profile—the pattern of which genes were active in vascular cells remained closer to what you’d see in a young kidney.

At the cellular level, the drug seemed to be working through multiple pathways. It restored the efficiency of mitochondrial function in endothelial cells and supporting vascular cells. The pathways involved in electron transport and ATP production—those energy-generating processes—were upregulated. Inflammatory signals were dampened. Most intriguingly, the drug seemed to partially reprogram vascular cells, maintaining them in a more stable, youthful state rather than allowing them to drift into the damaged configurations that characterise aged vessels.

The intercellular dialogue that had largely gone silent in untreated old kidneys was restored. The team could see this in their signalling analysis—the complex network of interactions between endothelial cells, support cells, and filtration cells was reactivated. The drug seemed to do more than simply reverse age-related losses. It appeared to reawaken communication networks that had fallen dormant, restoring what the researchers describe as a “regenerative and communicative vascular state.”

Perhaps most tellingly, when the researchers looked at the albumin leakage that characterises aged kidneys—that troublesome protein escaping into the urine—they found it was significantly reduced in treated fish. The filtering barrier was working better. The kidneys were functioning more effectively, despite the fact that all the other hallmarks of ageing were still present in these fish’s tissues.

The Translation Problem

None of this proved the drug would help human kidneys age more gracefully. But it’s suggestive. In rodent models of kidney disease, SGLT2 inhibitors have been shown to preserve vascular structure after injury. What’s novel here is seeing them work in an ageing context, in an animal where the decline happens in a timescale that lets researchers observe the complete process. The killifish isn’t just a faster aging model—it’s one where researchers can see mechanisms that would take decades to unfold in humans or mice.

The team notes in their report that the effects varied between males and females, with the protective vascular effects more pronounced in females. The drug also didn’t extend lifespan in the treated fish, an important reminder that preserving kidney structure doesn’t necessarily translate into living longer. But it did preserve kidney function—that’s what matters clinically. In patients with chronic kidney disease, the goal isn’t always to live dramatically longer. It’s to maintain the function that keeps you healthy, to slow the decline that eventually forces you toward dialysis or transplantation.

What’s remarkable about this research is how it reframes the ageing kidney. We often think of ageing as an inevitable process of decline, a running down of the biological clock that nothing can fundamentally alter. But these results suggest something more nuanced: the specific pathway of decline, the mechanisms that carry us from youth to age-related dysfunction, might be somewhat malleable. Change the metabolic environment. Restore the cellular conversation. Quiet the inflammatory fires. And the tissue responds, maintaining something closer to its youthful architecture.

The drug itself isn’t necessarily the answer—SGLT2 inhibitors might be just one possible intervention among many. What matters is what the research reveals about the process itself. The vascular rarefaction that defines kidney ageing isn’t a passive consequence of time passing. It’s an active process driven by specific, addressable mechanisms. Metabolic inflexibility. Inflammation. Loss of intercellular communication. Each of these, the killifish research suggests, might be a lever for intervention.

This is what translational research ought to look like—not the simple application of a drug to a disease, but the use of a model organism to uncover the fundamental mechanisms of decline, creating a foundation for rational intervention in human disease. The killifish lives fast, ages rapidly, and reveals its secrets quickly. In doing so, it might offer us a chance to slow human kidney ageing down.

That won’t happen tomorrow. But somewhere in the research pipeline, these results are making their way toward the next phase of investigation. And that’s worth watching for. Because for the hundreds of millions of people worldwide living with chronic kidney disease—people for whom slowing the decline is the difference between decades of function and years on dialysis—understanding what drives the vascular collapse, and finding ways to arrest it, isn’t a curiosity. It’s a possibility that could reshape the course of their lives.

Study link: https://www.kidney-international.org/article/S0085-2538(25)01020-8/fulltext